NYXH Overview

Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.

Wall Street analysts forecast NYXH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NYXH is10.41 USD with a low forecast of 5.82 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Nyxoah SA revenue for the last quarter amounts to 1.97M USD, increased 55.77

Nyxoah SA. EPS for the last quarter amounts to -0.63 USD, increased 26.00

Nyxoah SA (NYXH) has 147 emplpoyees as of March 10 2026.

Today NYXH has the market capitalization of 152.38M USD.